BioCryst Pharmaceuticals, Inc. (BCRX)
8.715
-0.04
(-0.40%)
USD |
NASDAQ |
Mar 02, 13:47
BioCryst Pharmaceuticals Research and Development Expense (TTM) : 164.74M for Dec. 31, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Anika Therapeutics, Inc. | 25.77M |
| KalVista Pharmaceuticals, Inc. | 55.64M |
| Lantheus Holdings, Inc. | 177.31M |
| Plus Therapeutics, Inc. | 7.624M |
| BioStem Technologies, Inc. | 6.878M |